During the past decade, Onkologische Schwerpunktpraxis - Leer conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis - Leer" #1 sponsor was "German CLL Study Group" with 5 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Celgene" with 1 trials sponsored and "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis - Leer" #1 collaborator was "German CLL Study Group" with 2 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "Arbeitsgemeinschaft fur Internistische Onkologie" with 1 trials as a collaborator, "Arbeitskreis Klinische Studien" with 1 trials as a collaborator and "Cancer International Research Group (CIRG)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis - Leer" are "Chronic Lymphocytic Leukemia" (6 trials), "Leukemia" (4 trials), "Advanced/Metastatic Breast Cancer" (1 trials), "Anal Cancer" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis - Leer" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis - Leer" are "Drug" (23 trials), "Biological" (6 trials), "Procedure" (3 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (4 trials), "Cyclophosphamide" (3 trials), "Fludarabine" (3 trials), "Placebo" (3 trials) and "radiation therapy" (3 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis - Leer" are 23 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis - Leer". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Onkologische Schwerpunktpraxis - Leer, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis - Leer, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".